vs
爵士制药（JAZZ）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是Reddit, Inc.的1.8倍（$1.2B vs $663.0M），Reddit, Inc.净利率更高（30.8% vs 17.0%，领先13.8%），Reddit, Inc.同比增速更快（69.0% vs 10.1%），爵士制药自由现金流更多（$345.8M vs $311.0M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 15.2%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
JAZZ vs RDDT — 直观对比
营收规模更大
JAZZ
是对方的1.8倍
$663.0M
营收增速更快
RDDT
高出58.9%
10.1%
净利率更高
RDDT
高出13.8%
17.0%
自由现金流更多
JAZZ
多$34.8M
$311.0M
两年增速更快
RDDT
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $663.0M |
| 净利润 | $203.5M | $204.0M |
| 毛利率 | — | 100.0% |
| 营业利润率 | 21.2% | 0.0% |
| 净利率 | 17.0% | 30.8% |
| 营收同比 | 10.1% | 69.0% |
| 净利润同比 | 6.5% | 680.0% |
| 每股收益（稀释后） | $3.34 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRDDT
| Q1 26 | — | $663.0M | ||
| Q4 25 | $1.2B | $725.6M | ||
| Q3 25 | $1.1B | $584.9M | ||
| Q2 25 | $1.0B | $499.6M | ||
| Q1 25 | $897.8M | $392.4M | ||
| Q4 24 | $1.1B | $427.7M | ||
| Q3 24 | $1.1B | $348.4M | ||
| Q2 24 | $1.0B | $281.2M |
净利润JAZZRDDT
| Q1 26 | — | $204.0M | ||
| Q4 25 | $203.5M | $251.6M | ||
| Q3 25 | $251.4M | $162.7M | ||
| Q2 25 | $-718.5M | $89.3M | ||
| Q1 25 | $-92.5M | $26.2M | ||
| Q4 24 | $191.1M | $71.0M | ||
| Q3 24 | $215.1M | $29.9M | ||
| Q2 24 | $168.6M | $-10.1M |
毛利率JAZZRDDT
| Q1 26 | — | 100.0% | ||
| Q4 25 | — | 91.9% | ||
| Q3 25 | — | 91.0% | ||
| Q2 25 | — | 90.8% | ||
| Q1 25 | — | 90.5% | ||
| Q4 24 | — | 92.6% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | — | 89.5% |
营业利润率JAZZRDDT
| Q1 26 | — | 0.0% | ||
| Q4 25 | 21.2% | 31.9% | ||
| Q3 25 | 5.1% | 23.7% | ||
| Q2 25 | -65.6% | 13.6% | ||
| Q1 25 | -6.2% | 1.0% | ||
| Q4 24 | 17.5% | 12.4% | ||
| Q3 24 | 24.7% | 2.0% | ||
| Q2 24 | 19.5% | -11.0% |
净利率JAZZRDDT
| Q1 26 | — | 30.8% | ||
| Q4 25 | 17.0% | 34.7% | ||
| Q3 25 | 22.3% | 27.8% | ||
| Q2 25 | -68.7% | 17.9% | ||
| Q1 25 | -10.3% | 6.7% | ||
| Q4 24 | 17.6% | 16.6% | ||
| Q3 24 | 20.4% | 8.6% | ||
| Q2 24 | 16.5% | -3.6% |
每股收益（稀释后）JAZZRDDT
| Q1 26 | — | $1.01 | ||
| Q4 25 | $3.34 | $1.24 | ||
| Q3 25 | $4.08 | $0.80 | ||
| Q2 25 | $-11.74 | $0.45 | ||
| Q1 25 | $-1.52 | $0.13 | ||
| Q4 24 | $2.97 | $4.76 | ||
| Q3 24 | $3.42 | $0.16 | ||
| Q2 24 | $2.49 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $1.4B |
| 总债务越低越好 | $5.4B | — |
| 股东权益账面价值 | $4.3B | $3.2B |
| 总资产 | $11.7B | $3.5B |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
现金及短期投资JAZZRDDT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $953.6M | ||
| Q3 25 | $1.3B | $911.7M | ||
| Q2 25 | $1.2B | $734.1M | ||
| Q1 25 | $1.9B | $635.7M | ||
| Q4 24 | $2.4B | $562.1M | ||
| Q3 24 | $2.2B | $515.9M | ||
| Q2 24 | $1.4B | $468.0M |
总债务JAZZRDDT
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — |
股东权益JAZZRDDT
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.3B | $2.9B | ||
| Q3 25 | $4.0B | $2.6B | ||
| Q2 25 | $3.7B | $2.4B | ||
| Q1 25 | $4.2B | $2.2B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.2B | $2.0B | ||
| Q2 24 | $3.8B | $1.9B |
总资产JAZZRDDT
| Q1 26 | — | $3.5B | ||
| Q4 25 | $11.7B | $3.2B | ||
| Q3 25 | $11.4B | $2.9B | ||
| Q2 25 | $10.9B | $2.6B | ||
| Q1 25 | $11.5B | $2.4B | ||
| Q4 24 | $12.0B | $2.3B | ||
| Q3 24 | $12.3B | $2.2B | ||
| Q2 24 | $11.4B | $2.1B |
负债/权益比JAZZRDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | — |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $311.0M |
| 自由现金流率自由现金流/营收 | 28.9% | 46.9% |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $868.6M |
8季度趋势，按日历期对齐
经营现金流JAZZRDDT
| Q1 26 | — | — | ||
| Q4 25 | $362.5M | $266.8M | ||
| Q3 25 | $474.6M | $185.2M | ||
| Q2 25 | $88.9M | $111.3M | ||
| Q1 25 | $429.8M | $127.6M | ||
| Q4 24 | $398.6M | $90.0M | ||
| Q3 24 | $398.7M | $71.6M | ||
| Q2 24 | $331.4M | $28.4M |
自由现金流JAZZRDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | $345.8M | $263.6M | ||
| Q3 25 | $459.4M | $183.1M | ||
| Q2 25 | $75.9M | $110.8M | ||
| Q1 25 | $415.9M | $126.6M | ||
| Q4 24 | $385.3M | $89.2M | ||
| Q3 24 | $388.0M | $70.3M | ||
| Q2 24 | $324.3M | $27.2M |
自由现金流率JAZZRDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | 28.9% | 36.3% | ||
| Q3 25 | 40.8% | 31.3% | ||
| Q2 25 | 7.3% | 22.2% | ||
| Q1 25 | 46.3% | 32.3% | ||
| Q4 24 | 35.4% | 20.8% | ||
| Q3 24 | 36.8% | 20.2% | ||
| Q2 24 | 31.7% | 9.7% |
资本支出强度JAZZRDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 0.4% | ||
| Q3 25 | 1.3% | 0.4% | ||
| Q2 25 | 1.2% | 0.1% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | 1.0% | 0.4% | ||
| Q2 24 | 0.7% | 0.4% |
现金转化率JAZZRDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | 1.06× | ||
| Q3 25 | 1.89× | 1.14× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | 2.09× | 1.27× | ||
| Q3 24 | 1.85× | 2.40× | ||
| Q2 24 | 1.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RDDT
暂无分部数据
